SCHEMBL190435

SCHEMBL190435

COc1ccccc1Oc1ccnc(Nc2nc(C)cs2)c1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.56
ALDH1A1 P00352 1/20 0.56
MAPT P10636 1/20 0.56
HPGD P15428 1/20 0.56
GCK P35557 9/20 0.56
RAB9A P51151 4/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
NPC1 O15118 2/20 0.51
TRPV4 Q9HBA0 1/20 0.50
TGFBR1 P36897 4/20 0.49
KCNN1 Q92952 1/20 0.47
KCNN2 Q9H2S1 1/20 0.47
KCNN3 Q9UGI6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190467 0.87 GCK (0.54) GAAALDH1A1MAPTHPGDGCK
SCHEMBL191828 0.87 GCK (0.54) GAAALDH1A1MAPTHPGDGCK
SCHEMBL190775 0.86 GCK (0.53) GAAALDH1A1MAPTHPGDGCK
SCHEMBL190659 0.85 GCK (0.59) GAAGCKRAB9AKMT2AMEN1
SCHEMBL190592 0.85 GCK (0.49) GAAALDH1A1MAPTHPGDGCK
SCHEMBL191592 0.85 TRPV4 (0.56) GAAALDH1A1MAPTHPGDGCK
SCHEMBL12305625 0.84 GCK (0.51) GAAALDH1A1MAPTHPGDGCK
SCHEMBL190648 0.84 GCK (0.66) GAAALDH1A1MAPTHPGDGCK
SCHEMBL191056 0.84 TRPV4 (0.56) GAAALDH1A1MAPTHPGDGCK
SCHEMBL190111 0.84 GCK (0.53) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GAA 35/4885ALDH1A1 1869/4885MAPT 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.